MEDREGEN

A multi-center international trial studying the immunoregulatory and regenerative potential of MRG-001 in severe and critically ill COVID-19 patients has been initiated by MedRegen.

MedRegen has successfully completed the phase I study in healthy volunteers. MRG-001 has demonstrated to be safe across all dosages and effective in the mobilization of stem cells.

MedRegen has teamed up with ICON plc to initiate its first clinical trial in healthy subjects to evaluate the safety, pharmacokinetics and pharmacodynamics of MRG-001 in San Antonio, Texas.